Prevalence and predictors of poor heart failure treatment outcomes in Ethiopia: a systematic review and meta-analysis.

IF 2.8 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Frontiers in Cardiovascular Medicine Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI:10.3389/fcvm.2024.1434265

Firomsa Bekele, Lalise Tafese, Ginenus Fekadu, Geleta Nenko Dube, Dinka Dugassa, Dagim Samuel

{"title":"Prevalence and predictors of poor heart failure treatment outcomes in Ethiopia: a systematic review and meta-analysis.","authors":"Firomsa Bekele, Lalise Tafese, Ginenus Fekadu, Geleta Nenko Dube, Dinka Dugassa, Dagim Samuel","doi":"10.3389/fcvm.2024.1434265","DOIUrl":null,"url":null,"abstract":"Background: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Various factors can exacerbate disease progression in patients with HF and negatively impact treatment outcomes. This study aims to evaluate the pooled prevalence and contributing factors associated with poor heart failure treatment outcomes in Ethiopia.Methods: A systematic review and meta-analysis were conducted using five databases: Google Scholar, ScienceDirect, Hinari, PubMed, and Scopus. In total, 12 studies met the eligibility criteria for inclusion in this analysis. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Data extraction was performed using a Microsoft Excel spreadsheet, and statistical analysis was conducted with STATA 14. The Joanna Briggs Institute Meta-analysis of Statistics Assessment and Review Instrument was utilized for quality assessment. Heterogeneity among the studies was evaluated using the I 2 statistic and the Cochrane Q test. Publication bias was assessed using Begg's test, Egger's weighted regression, and funnel plots.Results: The pooled prevalence of poor HF treatment outcomes was found to be 16.67% [95% confidence interval (CI): 10.67-22.67]. No significant heterogeneity was observed across the included studies (I 2 = 0.0%, p = 0.962). Significant predictors of a poor treatment outcome were smoking cigarettes [adjusted odds ratio (AOR) = 10.74; 95% CI: 3.24-35.63] and medication-related problems (AOR = 3.99; 95% CI: 1.90-8.37).Conclusion: The prevalence of poor HF treatment outcomes in Ethiopia was found to be high. Smoking cigarettes and medication-related problems are significant predictors of these adverse outcomes. Comprehensive health education and improved clinical pharmacy services are essential for addressing these issues.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023437397, PROSPERO (CRD42023437397).","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1434265"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703969/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2024.1434265","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Various factors can exacerbate disease progression in patients with HF and negatively impact treatment outcomes. This study aims to evaluate the pooled prevalence and contributing factors associated with poor heart failure treatment outcomes in Ethiopia.

Methods: A systematic review and meta-analysis were conducted using five databases: Google Scholar, ScienceDirect, Hinari, PubMed, and Scopus. In total, 12 studies met the eligibility criteria for inclusion in this analysis. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Data extraction was performed using a Microsoft Excel spreadsheet, and statistical analysis was conducted with STATA 14. The Joanna Briggs Institute Meta-analysis of Statistics Assessment and Review Instrument was utilized for quality assessment. Heterogeneity among the studies was evaluated using the I ² statistic and the Cochrane Q test. Publication bias was assessed using Begg's test, Egger's weighted regression, and funnel plots.

Results: The pooled prevalence of poor HF treatment outcomes was found to be 16.67% [95% confidence interval (CI): 10.67-22.67]. No significant heterogeneity was observed across the included studies (I ² = 0.0%, p = 0.962). Significant predictors of a poor treatment outcome were smoking cigarettes [adjusted odds ratio (AOR) = 10.74; 95% CI: 3.24-35.63] and medication-related problems (AOR = 3.99; 95% CI: 1.90-8.37).

Conclusion: The prevalence of poor HF treatment outcomes in Ethiopia was found to be high. Smoking cigarettes and medication-related problems are significant predictors of these adverse outcomes. Comprehensive health education and improved clinical pharmacy services are essential for addressing these issues.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023437397, PROSPERO (CRD42023437397).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

埃塞俄比亚不良心力衰竭治疗结果的患病率和预测因素：系统回顾和荟萃分析。

背景：心力衰竭（HF）是全世界发病率和死亡率的主要原因。各种因素可加剧心衰患者的疾病进展，并对治疗结果产生负面影响。本研究旨在评估埃塞俄比亚心力衰竭治疗结果不佳的综合患病率和相关因素。方法：采用谷歌Scholar、ScienceDirect、Hinari、PubMed和Scopus五个数据库进行系统综述和荟萃分析。总共有12项研究符合纳入本分析的资格标准。该综述遵循了2020年系统评价和荟萃分析指南的首选报告项目。数据提取采用Microsoft Excel电子表格，统计分析采用STATA 14。采用乔安娜布里格斯研究所统计荟萃分析评估和回顾工具进行质量评估。采用i2统计量和Cochrane Q检验评估研究间的异质性。采用Begg检验、Egger加权回归和漏斗图评估发表偏倚。结果：HF治疗结果不良的总发生率为16.67%[95%置信区间（CI）： 10.67-22.67]。纳入的研究间无显著异质性（i2 = 0.0%, p = 0.962）。不良治疗结果的显著预测因子是吸烟[校正优势比(AOR) = 10.74；95% CI: 3.24-35.63]和药物相关问题(AOR = 3.99；95% ci: 1.90-8.37)。结论：在埃塞俄比亚，心衰治疗结果不佳的发生率很高。吸烟和药物相关问题是这些不良结果的重要预测因素。全面的健康教育和改善临床药学服务是解决这些问题的关键。系统评价注册：https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023437397, PROSPERO （CRD42023437397）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.80

自引率

11.10%

发文量

3529

审稿时长

14 weeks

期刊介绍： Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.